| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Eli Lilly and Company (NYSE:LLY) today announced plans to open a new Lilly Gateway Labs (LGL) site in Philadelphia, bringing its distinctive model of scientific partnership to a city known for shaping the future of medicine.
The new Gateway Labs site will occupy 44,000 square feet of 2300 Market, a life sciences facility in Center City newly developed and operated by Breakthrough Properties. Biotechs based in the site will have access to dedicated, fully equipped wet lab facilities alongside the strategic scientific engagement that has been the hallmark of the Gateway Labs approach.
"Philadelphia has long led biotech innovation, from early vaccine development to pioneering gene therapy and CAR-T treatments and discovering new approaches to Alzheimer's disease. Today's local biotech scene builds on that legacy with founders tackling medicine's toughest challenges," said Julie Gilmore, Ph.D., vice president, and global head of Lilly Gateway Labs and Catalyze360 Portfolio Management. "Access to top-notch lab infrastructure is essential, but success for early-stage companies also requires experienced thought partners who understand the science and can help navigate the challenging journey from discovery through early clinical development."
Lilly's expanded Philadelphia presence underscores its strategy of establishing Gateway Labs sites in communities where research excellence and entrepreneurial ambition converge. Anchored by leading academic medical centers and serving a diverse patient population, Philadelphia has evolved as an upper tier life sciences innovation hub where foundational research rapidly advances toward clinical application. With the addition of Philadelphia, Gateway's U.S. footprint now includes four geographic centers of innovation, including Boston, South San Francisco, and San Diego. In each locale, Lilly Gateway Labs serves as a catalyst for community-building across life science sectors, synergizing the efforts of biotechs, venture partners, and other ecosystem partners.
Lilly Gateway Labs is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly ExploR&D, and Lilly TuneLab, which together support biotech innovation by providing access to strategic capital, lab space and technology, and research and development capabilities including advanced AI models. Since the first Gateway Labs site opened in 2019, resident companies have collectively raised more than $3 billion, fueling progress on over 50 therapeutic programs.
Posted In: LLY
